SaMD Series: The Interplay Between IP and FDA Submissions
July 30, 2018
By Shana K. Cyr, Ph.D.; Susan Y Tull
Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to intellectual property protection often follow. In this series, we take a close look at IP considerations that SaMD developers should be aware of as they enter this market. In this podcast, Finnegan partners Shana Cyr and Susan Tull explore the interplay between intellectual property and Food and Drug Administration (FDA) submissions for SaMD.
Tags
software as a medical device (SaMD), Food and Drug Administration (FDA), Podcast Series: Software as a Medical Device (SaMD)
